Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB)

Post time 2022-5-5 18:40:44

journal：JAMA Oncology

Authors：Esther N. Pijnappel; J. Annelie Suurmeijer; Bas Groot Koerkamp; Milan Kos; Jens T. Siveke; Roberto Salvia; Paula Ghaneh; Casper H. J. van Eijck; Faridi S. van Etten-Jamaludin; Ross Abrams; Birute Brasiūniene; Markus W. Büchler; Riccardo Casadei; Jean-Luc van Laethem; Jordan Berlin; Narikazu Boku; Thierry Conroy; Henriette Golcher; Marianne Sinn; John P. Neoptolemos; Geertjan van Tienhoven; Marc G. Besselink; Johanna W. Wilmink; Hanneke W. M. van Laarhoven

Published date：--

DOI：10.1001/jamaoncol.2022.0168

Article link：http://dx.doi.org/10.1001/jamaoncol.2022.0168

Article Source：American Medical Association (AMA)。

Remark：

Post time 2022-5-5 18:40:45

: This post has been completed
Completed attachments will be deleted within 24 hours.

[JAMA] Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB)

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[JAMA] Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB) Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[JAMA] Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB)